An interventional study of 2-Week Home Monitoring and 6-Week Home Monitoring in Postpartum, Hypertension and Hypertensive Disorder of Pregnancy, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by University of Minnesota · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hypertension by University of Minnesota — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · University of Minnesota.
Among the 23 studies in Hypertension by University of Minnesota, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 22nd registered.
6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.
Browse Hypertension studies →4 of the 23 studies in Hypertension by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 60+
University of Minnesota · Sites in United States
Ages 35–70 · Women only · Healthy volunteers
University of Minnesota · Sites in United States
Ages 45–65 · Women only
By country, each count listing its studies:
Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 1979; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 100 across 4,582 interventional studies indexed under Hypertension.
Median enrollment 79 across the 15 interventional studies, 81 across the 2 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Minnesota is the lead sponsor of 1,218 studies on the registry; 198 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
1 of the studies in Hypertension by University of Minnesota that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04439370University of MinnesotaAutonomic Regulation of Blood Pressure in Premature and Early Menopausal Women | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Hypertension by University of Minnesota, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postpartum remote blood pressure monitoring programs for patients with hypertensive disorders of pregnancy (HDP) are becoming part of standard postpartum management. Existing programs range in duration from 2 to 6 weeks but there has not been any evaluation as to what program duration is optimal. The primary objective of this study is to evaluate the impact of program duration on clinical outcomes for patients participating in a single institution's postpartum remote blood pressure monitoring program for patients with HDP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized into the 2 week arm will be immediately unenrolled from the postpartum remote blood pressure monitoring program and resume standard postpartum care
Diagnostic Test: 2-Week Home Monitoring
Patients randomized into the 6 week arm will continue and complete the program in its entirety per current SOC (4 additional weeks)
Diagnostic Test: 6-Week Home Monitoring
Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.
HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.
Diastolic Blood Pressure
The primary outcome will be the patient's diastolic blood pressure (DBP) at their 6-week postpartum visit.
Time frame: Week 6
Systolic Blood Pressure at 6 weeks post-partum
Patient's systolic blood pressure at their 6-week postpartum visit
Time frame: Week 6
6-Week Post-partum Follow-up Rates
Participants who complete a 6-week post-partum visit / Total participants eligible for a 6-week post-partum visit
Time frame: Week 6
Unscheduled OB visit, triage visit, ED visit, or readmission rates
Time frame: Week 6
Patient Satisfaction Survey responses at 6 weeks
PSS Score, where higher score indicates greater satisfaction
Time frame: Week 6
Rate of severe hypertension
defined as systolic blood pressure ≥ 160mmHg and/or DBP ≥ 110 mmHg
Time frame: Week 6
Rate of new hypertension diagnosis at 6 weeks postpartum
based on American Heart Association and American College of Cardiology criteria (AHA/ACC)
Time frame: Week 6
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.
Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.
Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.